US 6,982,252 B2
Inhibition of vacuolar proton ATPase activity and/or the modulation of acidic organelle function sensitizes cells to radiation, chemotherapy and biological agents
Shoshana Paglin, New York, N.Y. (US); Joachim Yahalom, New York, N.Y. (US); Timothy Hollister, Chicago, Ill. (US); and Thomas Delohery, Oakland, N.J. (US)
Assigned to Memorial Sloan-Kettering Cancer Center, New York, N.Y. (US)
Filed on Dec. 04, 2001, as Appl. No. 10/6,957.
Claims priority of provisional application 60/251153, filed on Dec. 04, 2000.
Prior Publication US 2002/0156025 A1, Oct. 24, 2002
Int. Cl. A01N 43/04 (2006.01); A01N 43/02 (2006.01); A61K 31/70 (2006.01); A61K 31/335 (2006.01)
U.S. Cl. 514—28 22 Claims
 
1. A method for promoting cell death of a cell which has been exposed to a chemotherapeutic agent comprising contacting said cell with benzolaetone enamide that is an inhibitor of vacuolar proton ATPase activity within about 48 hours of the first exposure to the chemotherapeutic agent in an amount effective to prevent formation of acidic vesicular organelles in said cell, thereby promoting cell death.